Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Uterine Cervical Neoplasms 3 Esophageal Neoplasms 3 Lymphatic Metastasis 2 Esophageal Squamous Cell Carcinoma 2 Carcinoma, Non-Small-Cell Lung 2 Recurrence 1 Pathologic Complete Response 1 Neoplasm Metastasis 1 Melanoma 1 Carcinoma, Squamous Cell 1 Breast Neoplasms 1

Interventions

Cyclophosphamide 17 fludarabine 13 Dexamethasone 12 Cisplatin 11 Rituximab 10 Gemcitabine 9 Paclitaxel 7 Lenalidomide 7 Decitabine 7 Cytarabine 7 Bendamustine Hydrochloride 7 fludarabine phosphate 6 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6 Etoposide 6 Carboplatin 6 Bortezomib 6 Radiotherapy 5 Injections 5 Azacitidine 5 camrelizumab 4 apatinib 4 Valproic Acid 4 Thalidomide 4 Procarbazine 4 Oxaliplatin 4 Drug Therapy 4 Antilymphocyte Serum 4 tislelizumab 3 pomalidomide 3 liposomal doxorubicin 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Recurrence × TP protocol × Clear all

NCT01405235 2012-04-12

AGO-Zervix-1

Institut fuer Frauengesundheit

Phase 3 Unknown

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡